e.l.f. Beauty reports fiscal Q4 results on May 20 against a backdrop of heavy short interest that is quietly unwinding, a stock down sharply on the month, and a Wall Street consensus that remains bullish in rating but increasingly cautious on price.
Short sellers have been active but are pulling back ahead of the print. Short interest is running at nearly 12% of the free float — a meaningful level — yet has fallen about 2.7% over the past week and slipped further on Friday to roughly 7.15 million shares. The month-over-month picture is more mixed: shorts built positions aggressively in mid-April, pushing share counts above 8.4 million, before retreating sharply after April 23. The borrow market reflects little urgency on either side. Cost to borrow is just 0.49% — effectively negligible — and availability is loose at 173%, well above the 52-week trough of 131%. There is no squeeze pressure here. Options traders are actually leaning bullish into the event: the put/call ratio has dropped to 0.68, more than a standard deviation below its 20-day average of 0.72, placing it near the most call-skewed reading of the past year.
The analyst community is unified in one direction: down. Every major firm has cut its price target in recent months. JP Morgan trimmed to $85 from $105 in April while holding Overweight. Bank of America cut to $93 from $115, also maintaining Buy. Most recently, Canaccord Genuity lowered its target to $100 from $121 on May 18, keeping a Buy rating. The lone notable downgrade came from Morgan Stanley, which moved to Equal-Weight from Overweight on May 1, cutting its target to $67 — a signal that at least one bellwether firm has lost conviction on the near-term setup. The consensus mean target sits at $90, implying roughly 60% upside from the current price of $56.43. That gap is striking, but it reflects how far the stock has fallen — down 18% in a month and around 26% year-to-date — rather than a sudden burst of analyst enthusiasm.
The bull-bear debate centers on growth durability. Bulls point to extraordinary first-half fiscal 2025 sales growth, record market share in eye products, and an international expansion cycle that is still building, with door additions weighted toward the second half. Bears counter that the cheek category — historically a core strength — has seen share fall to a multi-year low of 31%, that tough year-over-year comparisons loom in the near term, and that forward margin assumptions have been trimmed. The EPS momentum picture is split: the 30-day reading ranks in just the 19th percentile, suggesting recent estimate cuts, while the 90-day figure sits in the 92nd percentile, reflecting how dramatically earnings expectations have shifted over the broader period. Closest peers have also struggled this week — Estée Lauder fell nearly 7% and Coty dropped more than 16% — suggesting sector-wide pressure rather than an ELF-specific dislocation.
The May 20 print will test whether e.l.f. Beauty's growth story is merely decelerating or genuinely breaking down — and whether management's international expansion narrative is enough to offset mounting evidence of domestic category share losses.
See the live data behind this article on ORTEX.
Open ELF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
